← Back to patent-cliff list
BMS-986166
Tier C — Watch / tradeBMS-986166
Bristol Myers Squibb
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：S1PR1
Indications (approved)：Atopic dermatitis, Ulcerative colitis
Regional status
US
Phase II
2021-08-17
EU
Phase II
2021-08-17
China
IND filed
2022-05-06
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of BMS-986166?
Approved indications include: Atopic dermatitis, Ulcerative colitis.
When does the BMS-986166 patent expire?
No public expiry year is available for BMS-986166 yet; this page updates once verified.
How do I get a quote for BMS-986166 intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-06